Profile

AVAXIM® Junior is indicated for active immunisation against infection caused by hepatitis A virus (HAV) in children aged 1 - 15 years.1

Before you prescribe this vaccine please refer to the Prescribing Information and SmPC link.

AVAXIM® Junior confers immunity through inducing the production of anti-HAV antibodies.1

A full immunisation course consists of 2 doses, 1 primary dose followed by a booster dose, for full protection.1

AVAXIM® Junior paediatric vaccine can be used for both primary and booster immunisation.
The vaccine is a ready-to-use suspension for injection containing 80 antigen units of inactivated HAV, half the antigen dose of the adult AVAXIM® (hepatitis A vaccine [inactivated, adsorbed]) vaccine.1,2

Why help protect your patients with AVAXIM® Junior?

Hepatitis A remains one of the most common travel-related vaccine preventable diseases, although the incidence in travellers is declining.3

Hepatitis A is caused by a virus which is usually acquired through the consumption of food or water contaminated by human faeces. Foods such as undercooked meat and fish can be a risk as well as foods that grow close to the ground such as lettuce and strawberries. It can also be acquired through person to person contact.3

The risk of acquiring hepatitis A is highest in low-income countries with poor sanitary conditions. Regions where hepatitis A is highly endemic include the Indian sub-continent (particularly Bangladesh, India, Nepal and Pakistan), Sub-Saharan and North Africa, parts of the Far East (except Japan), South and Central America and the Middle East.3

There is no specific treatment for hepatitis A. Protection is through effective personal and food and water hygiene and immunisation.3

Watch the video below to learn more about hepatitis A in children and the protection that AVAXIM® Junior can offer them.

Prescribing Information can be accessed via the below link
AVAXIM® Prescribing Information UK
AVAXIM® Jr Prescribing Information UK 

Learn more about Avaxim® Junior and hepatitis A.

Evidence

  • AVAXIM® Junior offers rapid protection against hepatitis A as early as 2 weeks from the first dose.1,4,5

    Seroconversion rates across different ages after primary immunisation with AVAXIM® Junior*✝4

    Seroprotection rates and GMCs in a subgroup of Argentinian children after primary and booster doses of AVAXIM® Junior.‡5

  • AVAXIM® Junior offers long-lasting protection against hepatitis A.1,7,8
     

    GMCs in Argentinian children followed after immunisation with AVAXIM® Junior.**7,8

    In a follow-up study in Argentinian children, 97.9% (47/48) of children with data available 10 years after primary immunisation with AVAXIM® Junior were seropositive for anti-HAV antibodies (≥20 mIU/ml). Up to 15 years after initial immunisation, all of the 30 children with data still available were found to be seropositive for anti-HAV antibodies.7,8

Usage

  • AVAXIM® Junior offers a flexible timing for booster immunisation.1

    In order to provide long-term protection, a booster dose should be given between 6 months to 10 years after the first dose.1

    For further details on the clinical rationale for this please see the Evidence and Sustained Seroprotection section.

  • AVAXIM® Junior can be used as a booster in children who have previously been immunised with another inactivated hepatitis A vaccine.1

    Seroprotection rates 4 weeks after 2 doses of a paediatric inactivated hepatitis A vaccines.

    §Data from initially HAV-seronegative children. Local and systemic adverse events were reported in 17% (72/424) of subjects following the first dose and in 19% of (80/415) subjects following the second dose. Pain was the most commonly reported adverse event (11.5% of all vaccinated subjects). All the reported local and systemic adverse events were mild in nature. No subjects were withdrawn from the study because of serious adverse events after any vaccine dose.

    Turkish children aged 1-15 years who had received a primary dose of either AVAXIM® Junior, Havrix Junior Monodose® or VAQTA® Paediatric were then given a booster dose of either the same vaccine or AVAXIM® Junior 6 months later. 4 weeks after the booster dose, seroprotection rates were 100% regardless of the immunisation combination used.6

Safety

Safety and Tolerability

AVAXIM® Junior is generally well tolerated in children aged 1–15 years.9

Based on data from a pooled analysis‡‡, most undesirable effects following administration of AVAXIM® Junior were limited to the first few days following immunisation, with spontaneous recovery. Reactions were more rarely reported after the booster dose than after the first dose.1

    Adverse reactions

    Frequency after any given doses§§

    Immune system disorders  
    Anaphylactic reaction Not known
    Metabolism and nutrition disorders  
    Appetite decrease Common
    Psychiatric disorders  
    Abnormal crying Very common
    Irritability Common
    Insomnia Common
    Nervous system disorders  
    Headache Very common
    Vasovagal syncope in response to injection Not known
    Convulsions with or without fever Not known
    Gastrointestinal disorders  
    Abdominal pain Common
    Diarrhoea Common
    Vomiting Common
    Nausea Common
    Skin and subcutaneous tissue disorders  
    Rash Uncommon
    Urticaria Uncommon
    Musculoskeletal and connective tissue disorders  
    Arthralgia Common
    Myalgia Common
    General disorders and administration site conditions  
    Injection site pain Very common
    Malaise Very common
    Pyrexia Common
    Injection site erythema Common
    Asthenia or drowsiness Common
    Injection site induration or oedema Common
    Injection site haematoma Common


    Before you prescribe this vaccine please refer to the Prescribing Information above.

Ways to order

You can order Sanofi Vaccines in two ways: online at VAXISHOP or through our call centre.

Order patient materials

Through Medisa we provide you and your patients with a variety of support materials including patient leaflets and in-surgery display items. You can quickly search for and order the materials you need.

Smarter Traveller

Direct your patients to the
Smarter Traveller website to find tips and advice on protecting their health while abroad.

    *Seroconversion defined as anti-HAV antibody titers rising from <20 mIU/ml (seronegative) to ≥20 mIU/ml.

    ✝Data from initially HAV-seronegative Israeli children. Rates of systemic reactions were 23.8% after the 1st dose and 11.4% after the booster dose. Pain at the injection site was the most common local reaction, though this did not persist longer than 3 days. Gastrointestinal tract disorder, headache and fever were the most common systemic reactions

    Immediate adverse reactions were observed in 0.6% (3/537) of subjects after the first dose. Local reactions were mild and transient and did not increase with subsequent doses. Among the systemic events reported during the 7-day follow-up period, 37 cases of fever after the first dose and 22 cases after the second dose were reported. Only 3 cases of fever were clearly related to immunisation (≤38.2°C) after the first injection, all of which subsided in less than 1 day.

    §Data from initially HAV-seronegative children. Local and systemic adverse events were reported in 17% (72/424) of subjects following the first dose and in 19% of (80/415) subjects following the second dose. Pain was the most commonly reported adverse event (11.5% of all vaccinated subjects). All the reported local and systemic adverse events were mild in nature. No subjects were withdrawn from the study because of serious adverse events after any vaccine dose.

    **GMC values may differ from initial studies due to a different number of children included in the follow-up studies.

    ‡‡Pooled analysis integrated data from 5,458 children aged 1–15 years, who received at least one injection of AVAXIM® Junior during clinical trials.

    §§Adverse event information is derived from clinical studies and worldwide post-marketing experience. Within each system organ class the adverse events are ranked under headings of frequency, using the following Council for International Organizations of Medical Sciences frequency rating: Very common ≥10%; Common ≥1 and <0.1%; Very rare < 0.01%; Not known (cannot be estimated from available data).

    HAV, hepatitis A virus; GMC, geometric mean concentration

    1. AVAXIM® Junior Summary of Product Characteristics.
    2. AVAXIM® Summary of Product Characteristics.
    3. Travel Health Pro. Hepatitis A. Available at: https://travelhealthpro.org.uk/factsheet/21/hepatitis-a (Accessed August 2023).
    4. Dagan R, et al. Vaccine. 1999;17(15–16):1919–25.
    5. López EL,et al. Pediatr Infect Dis J. 2001;20(1):48–52.
    6. Soysal A, et al. Eur J Pediatr. 2007;166(6):533–9.
    7. López EL, et al. PediatrInfect Dis J. 2010;29(6):568–70
    8. López EL, et al. Pediatr Infect Dis J. 2015;34(4):417–25.

MAT-XU-2301296 (v2.0) 
Date of preparation: August 2023